^
Association details:
| Biomarker: | MLL-AFF1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SENSITIVITY TO VENETOCLAX IN BCP-ALL IS CLOSELY CORRELATED TO HIGH FUNCTIONAL BCL-2 DEPENDENCE AND CAN BE ENHANCED BY DEPLETION OF MCL-1
Published date:
05/17/2018
Excerpt:
...we evaluated activity and predictive models for the BCL-2 inhibitor venetoclax (VEN) in BCP-ALL and investigated co-targeting of MCL-1 to increase VEN sensitivity....however high VEN sensitivities were identified in one sample with a MLL-AF4 fusion, in line with previous reports, and in two TP53 mutated cases.
